SAB Biotherapeutics (SABS) Stock Forecast: StockMap's 2-Week Call
SABS stock forecast: StockMap's model makes no two-week call on SAB Biotherapeutics after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 3 of 5 two-week windows on SABS since Aug 24; by chance, a call on the same dates was right 58% of the time.
SAB Biotherapeutics last closed at $2.91, -9.06% on the session.
Against the IVW growth benchmark the position is -6.73% over the forecast window.
SAB Biotherapeutics' market cap is $262.17M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -3 (too close to call).
Where SABS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
21 daily calls for SABS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks SAB Biotherapeutics in the 33rd percentile on return on equity, where 100 is best.
SAB Biotherapeutics is classified under Health Care / Biotechnology.
StockMap tracks SAB Biotherapeutics as the 216th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite SAB Biotherapeutics ranks 75th of 394 in the group, against a group median of -0.27.